GYRE

Gyre Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for neurological and psychiatric disorders. Headquartered in San Francisco, California, the company was founded in 2019 and specializes in creating novel small molecule treatments targeting conditions with significant unmet medical needs. Gyre's lead product candidate, GYR-1001, is currently in Phase 2 clinical trials for treatment-resistant depression, while its secondary pipeline includes GYR-2002 for anxiety disorders and GYR-3003 for cognitive impairment associated with schizophrenia. The company employs approximately 85 people across its San Francisco headquarters and research facility in South San Francisco. In 2023, Gyre completed a $68 million Series B financing round led by prominent venture capital firms to advance its clinical programs and expand its research capabilities. The company operates through partnerships with academic medical centers and contract research organizations to conduct its clinical trials across multiple sites in North America and Europe. Gyre's business model centers on in-house drug discovery and development through Phase 2 trials, with plans to pursue strategic partnerships for late-stage development and commercialization. The company maintains an intellectual property portfolio of over 25 issued and pending patents covering its drug candidates and proprietary screening technologies.